← Back

Brangista, Inc.

Brangista Inc. produces and publishes e-magazines, primarily in Japan. It operates through three segments: Promotion Support, Media, and Solutions. The Promotion Support business offers promotional tools that let users use photos and videos of famous talents for a fixed monthly fee. The Media Business publishes e-magazines such as Tabiiro, a travel e-magazine, and operates TravelNote, which provides information on domestic and overseas travel, tourist spots, restaurants, and hotels, and also offers services such as advertising in electronic magazines and commissioned production of electronic magazines. The Solutions Business provides website creation and operation services, along with consulting, page creation, analysis, and promotion services, including solutions for Japanese and local companies operating in Taiwan. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.

Country
Price · split & dividend adjusted
News & notes moving 6176.JP
6176.JP▲

gumi Rises for First Time in Three Days, Stimulated by SBI's Additional Acquisition of Brangista

gumi rose for the first time in three days. The previous day, September 3, SBI Holdings announced that it would acquire additional shares of Brangista through its subsidiary SBINM to strengthen business consolidation, and expectations are growing that this could also be a tailwind for gumi, which is also advancing business collaboration with the SBI Group. Meanwhile, Brangista saw a rush of buying from the morning and was indicated at its limit-up price.
6176.JP ▲3903.JP ▲8473.JP ▲
gamebiz·15dRead more →
Biotech & Genomic Medicine

Caion Signs Joint Research Agreement with FRONTEO for AI Drug Discovery

Caion has entered into a joint research agreement with FRONTEO regarding AI drug discovery. Additionally, CAPITA will record a special gain in the second quarter of the fiscal year ending March 2027 due to the sale of idle land. JMHD has revised down its consolidated earnings forecast for the fiscal year ending July 2026. Nexera has received a milestone payment of $86 million from Centessa based on progress in late-stage development. DWTi has decided on a domestic development plan for its glaucoma treatment agent H-1337. Blangista has seen additional share acquisition by SBINM LLC in connection with the strengthening of capital ties with SBI.
2158.JP ▲4565.JP ▲4576.JP ▲CPI.LSE ▲6176.JP 8473.JP
Biotech & Genomic Medicine
ウエルスアドバイザー·15dRead more →
© 2026 MarketDXAsset